* Supernus Pharmaceuticals Inc reported quarterly adjusted earnings of 69 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 24 cents. The mean expectation of four analysts for the quarter was for earnings of 44 cents per share. Wall Street expected results to range from 35 cents to 55 cents per share.
* Revenue rose 14.2% to $175.69 million from a year ago; analysts expected $157.30 million.
* Supernus Pharmaceuticals Inc's reported EPS for the quarter was 69 cents.
* The company reported quarterly net income of $38.5 million.
* Supernus Pharmaceuticals Inc shares had risen by 11.3% this quarter and gained 19.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 2.9% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc is $39.00 This summary was machine generated from LSEG data November 5 at 07:54 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.44 0.69 Beat
Jun. 30 2024 0.39 0.36 Missed
Mar. 31 2024 0.38 0.26 Missed
Dec. 31 2023 0.55 0.89 Beat
Comments